Article from Cloud-based Medicine Studio | A national authoritative medical organization for rare diseases will be established, and the second list of rare diseases will be updated
(attachments: the first list and the national reimbursement drug list)

Jan 31, 2023

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in china

Jan 18, 2023

CANbridge Congratulates Apogenix on First Patient Dosed in Asunercept (CAN008) Phase 3 Trial for the Treatment of COVID-19

-CANbridge holds exclusive rights for the development of CAN008 for any indication in Greater China

-CAN008 currently in Phase 2 trial for the treatment of glioblastoma multiforme in China

Jan 05, 2023

CANbridge Consolidates Gene Therapy Portfolio

-Secures Exclusive Global Rights to Potentially Best-in-Class Spinal Muscular Atrophy Gene Therapy from UMass Chan Medical School

-Completes Technology Transfer of Two Gene Therapies for Lysomal Storage Diseases

Jan 04, 2023